Plateletpheresis concentrates produced in 30 minutes along with plasma and packed red cells: Preliminary results

Valbonesi, M; Frisoni, R; Capra, Carlo; Lercari, G; Fella, M; Pittaluga, P.A.

doi:10.1002/jca.2920040403

Cited by 9 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concept of multicomponent donation has expanded from the field of autologous to the field of homologous donations. In the late 80s, Valbonesi et al reported on the concurrent collection of PLT concentrates in 30 min along with plasma and RBCs in allogeneic donors [10]. A technique was developed that allowed the collection of 3AE68 · 10 11 PLTs, 250 ml of plasma, and 225 ml RBCs with an Hct of 66AE5%.…”

Section: Introductionmentioning

confidence: 99%

Feasibility and safety of multicomponent apheresis donation

Moog

2011

ISBT Science Series

View full text Add to dashboard Cite

Background and Objectives Modern apheresis devices offer the possibility to collect blood components that are well standardized, as compared with those available with manual whole blood donations. Recent technologic advances in multicomponent donation have made possible the development of systems that can collect different blood components from the same donor during one apheresis session. Red blood cells (RBCs) can be concurrently collected with plasma or platelets (PLTs).Materials and Methods A PLT yield of ‡2 · 10 11 per unit according to European guidelines can be targeted by the algorithm of the blood cell separators after entering donor specific parameters such as body weight, height and blood counts. Furthermore, two units of RBCs can also be collected during one apheresis session provided that the donor fulfils the eligibility criteria for that procedure.Results The haemoglobin content of apheresed RBCs after addition of additive solution is higher than the minimal European requirement of whole blood derived RBCs of 40 g per unit due to standardization. Automated blood cell separators permit predictable collection of blood components with consistent yields and volumes. Repeat apheresis donors accept multicomponent donation and consent to concurrent component collection in >90% of the procedures. The results of a national survey showed that approximately 75% were willing to give an additional RBC unit four times per year. This allows blood centres to increase the number of units colleted at low extra costs. Collecting an additional RBC unit in plateletpheresis causes extra costs of approximately 20€ for disposables and work load compensating the production costs with respect to the selling price. The incidence of acute adverse events in multicomponent apheresis was reported with less than 1%. Small, female donors with lower pre-donation haematocrit were at higher risk for adverse events, especially when RBCs were collected. Double unit RBC collection showed to be safe if special eligibility criteria were respected.Conclusion Previous definitions of blood component yield and volume as well as the flexibility to collect those multicomponents allow the blood centre to collect those components that maximize donors' contribution and to meet the demands of its area hospitals for blood components. Blood transfusion services are progressively increasing their reliance on apheresis technology to optimize the number of blood components collected per donor visit and to reduce the number of donors a patient is exposed to. The use of these systems has shown at the same time that multicomponent donations have been well tolerated by the donors and are cost-effective.

show abstract

Section: Introductionmentioning

confidence: 99%

Feasibility and safety of multicomponent apheresis donation

Moog

2011

ISBT Science Series

View full text Add to dashboard Cite

show abstract

“…Since we had difficulty attaining such results routinely in our hemapheresis unit, we decided to modify the standard Fresenius procedure in order to reduce the needleto-needle time to less than 60 min and to collect more than 4 X 10" platelets, as we normally do with other blood cell separators [4,5,6]. A study was started with 45 donors enrolled in accordance with the Italian regulations for blood donation [7].…”

Section: Introductionmentioning

confidence: 99%

Plateletpheresis with the new fresenius AS 104 blood cell separator

Valbonesi

Frisoni

Fella

et al. 1991

J of Clinical Apheresis

View full text Add to dashboard Cite

Among the many blood cell separators introduced into the international market in these last few years, the Fresenius AS 104 represents an advanced and safe thrombocytapheresis machine whose development took advantage of extensive worldwide experience with blood cell separation. Nonetheless the AS 104 has generated most interest in West Germany and most, if not all, the studies published on its platelet collection efficiency have been carried out in that country. It is normally reported that from 2.7 to 3.5 x 10(11) platelets can be collected in approximately 80 minutes. Since these results could not be duplicated routinely in our hemapheresis unit, we set up a study by modifying the standard procedure. It was possible to reduce the procedure time and to collect platelet concentrates containing more than 4 x 10(11) cells on a routine basis by using the following procedure: ACD-A/blood ratio 1:10; Interface position 6:2; blood flow rate always exceeding 65 mL/min; rpm 1750; cell collection from 4 to 7 mL/min; volume of blood processed 3.6 L followed by the rinsing of the system with 200 ml of saline; extraction of the content of the secondary separation chamber by the action of the plasma pump working at 20 mL/min for 2 min. With this procedure the platelet yield in 34 collections exceeded 3.1 x 10(11) and averaged 4.06 x 10(11). The procedure time was reduced to 56.5 minutes with a mean blood flow rate of 62.3 mL/min. The leukocyte and erythrocyte contamination of the products were in the range of 1 x 10(7) and 1 x 10(8) respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Single‐donor platelet concentrates produced along with packed red blood cells with the haemonetics MCS 3p: Preliminary results

Valbonesi

Frisoni

Florio

et al. 1994

J of Clinical Apheresis

Self Cite

View full text Add to dashboard Cite

There has been an increasing interest in recent years over the qualitative superiority of single-donor platelets in the management of hemato-oncologic patients. The reasonable desire of both patients and physicians to limit the risks of transfusion along with the need for limiting the costs involved in this kind of therapy have led to application of multicomponent donations both in terms of double platelet concentrates and double products such as red blood cells (RBC) and platelets from the same donor. Single donor platelets and RBC have been collected in a semi-automated mode and only the very recent introduction of the Haemonetics MCS 3p with its SDP/RBC protocol provides a totally closed-system automated protocol for this combined collection. Twenty procedures have been carried out so far at our unit. In a mean of 87 minutes (6-7 passes), a mean of 3.1 x 10(11) platelets were collected along with approximately 220 mL of packed RBC. The leukocyte contamination of the platelet product was in the range of 0.4-1.1 x 10(7) (99% lymphocytes), and the quality of platelets was very satisfactory as measured by the hypotonic shock response, aggregation induced by ADP, collagen and ristocetin, morphology score, and membrane glycoproteins modifications. Equally satisfactory was the quality of the RBC concentrate, suspended in 80 mL of SAG-M, with a total hemoglobin (Hb) content approaching 55 g as compared to the normal Hb content of a standard RBC concentrate that is approximately 62 g.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Plateletpheresis concentrates produced in 30 minutes along with plasma and packed red cells: Preliminary results

Cited by 9 publications

References 3 publications

Feasibility and safety of multicomponent apheresis donation

Feasibility and safety of multicomponent apheresis donation

Plateletpheresis with the new fresenius AS 104 blood cell separator

Single‐donor platelet concentrates produced along with packed red blood cells with the haemonetics MCS 3p: Preliminary results

Contact Info

Product

Resources

About